Patent application number | Description | Published |
20100137308 | Quinoxaline Compounds and Use Thereof - The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 06-03-2010 |
20100240658 | Oxadiazole Derivatives - The invention relates to compounds of formula I: | 09-23-2010 |
20100305104 | Oxadiazole Diaryl Compounds - The invention relates to compounds of formula (I): | 12-02-2010 |
20110230518 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases. | 09-22-2011 |
20110257170 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES - This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers. | 10-20-2011 |
20110293564 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES - This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other deseases like cancers. | 12-01-2011 |
20120022109 | OXADIAZOLE DERIVATIVES - The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis. | 01-26-2012 |
20120035226 | OXADIAZOLE DERIVATIVES - The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis. | 02-09-2012 |
20130109676 | Oxadiazole Diaryl Compounds | 05-02-2013 |
20150018343 | Tetraaza-cyclopenta[a]indenyl and their use as Positive Allosteric Modulators - The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator. | 01-15-2015 |